Main sectors for revenues:

• Dermatology
• Aesthetic medicine
• Therapeutic dermatology

TOP 3 markets and their percentage shares:

1. USA: 40%
2. Europe: 30%
3. Asia-Pacific: 20%

Galderma Group AG mainly generates its revenues from dermatology, with a significant portion coming from aesthetic medicine. The USA is the largest market for Galderma, followed by Europe and the Asia-Pacific region. These markets significantly contribute to the revenue as they have a high demand for dermatological and aesthetic products.

Production Sites: Switzerland, Sweden, France, Canada, USA

Galderma Group AG produces its products at several international locations. The main production sites are located in Switzerland, Sweden, and France, highlighting the company's European presence. In addition, Galderma also has production capacities in Canada and the USA to efficiently serve the North American market.

This geographical distribution enables Galderma to flexibly respond to market demands and optimize supply chains. The strategic positioning of the production sites also supports research and development, as some of these locations are closely linked to the company's R&D centers.

Revenue Growth: Estimated 10-12% annually (2025-2027)

Focus Areas: Dermatology, aesthetic medicine, Prescription products

Galderma Group AG pursues a strategy that is strongly focused on innovation and expansion in dermatology and aesthetic medicine. The company plans to expand its product range through targeted research and development, especially in the areas of skincare and aesthetic treatments.

Another strategic focus is on geographical expansion into high-growth markets, particularly in Asia and Latin America. Galderma also invests in digital platforms and technologies to enhance customer loyalty and improve direct access to end consumers.

Additionally, the company relies on strategic partnerships and acquisitions to strengthen its market position and introduce new technologies and products to the market more quickly. This strategy is intended to support Galderma's sustainable growth and market leadership in the global dermatology industry.

Main raw materials: Hyaluronic acid, collagen, silicone, various pharmaceutical active ingredients

Countries of origin:

• Hyaluronic acid: China, Japan
• Collagen: USA, Brazil
• Silicone: Germany, USA
• Pharmaceutical active ingredients: India, Switzerland

Galderma Group AG, as a leading company in the field of dermatology, imports a variety of raw materials necessary for the production of its products. Hyaluronic acid and collagen are key components for their aesthetic and dermatological products. These are mainly sourced from China, Japan, and the USA, as these countries are leading in the production of these materials.

Silicone, used in many medical and cosmetic applications, is predominantly imported from Germany and the USA, where it is produced in high quality.

In addition, Galderma sources pharmaceutical active ingredients from India and Switzerland, known for their advanced pharmaceutical industries. These active ingredients are essential for the development and production of medications and dermatological treatments.

Market share in dermatology: 17% (2024)
Research and development investments: 12% of revenue (2024)
Patent portfolio: Over 500 active patents (2024)

Galderma Group AG has a significant competitive advantage in the field of dermatology, as evidenced by its high market share of 17%. This demonstrates that the company is capable of serving and dominating a considerable portion of the market.

Another important aspect is the continuous investment in research and development, which accounts for 12% of revenue. These investments enable Galderma to develop innovative products and differentiate itself from the competition.

In addition, Galderma has a strong patent portfolio with over 500 active patents. This protects their innovations and secures their market position in the long term. The competitive advantage is strengthened by these strategic measures, ensuring the company a leading role in the industry.

Institutional investor share: 65% (2025, estimated)
Insider purchases: No significant purchases in the last year
Insider sales: 2% of shares in the last year (2025, estimated)

The institutional investor share in Galderma Group AG is estimated at 65%. This demonstrates the confidence of major financial institutions in the company.

In 2025, there were no significant insider purchases, indicating that the management may not see significant undervaluations of the company. However, about 2% of the shares were sold by insiders, which could suggest profit-taking or personal financial decisions.

This information can help investors better assess market sentiment and confidence in the company's future development.

Market share of Galderma Group AG: 12% (2025, estimated)

Main competitors and their market shares:

1. Johnson & Johnson: 18%
2. L'Oréal: 15%
3. Galderma Group AG: 12%
4. Allergan (part of AbbVie): 10%
5. Beiersdorf AG: 8%
6. Estée Lauder Companies: 7%
7. Shiseido Company: 6%
8. Coty Inc.: 5%
9. Amorepacific Corporation: 4%
10. Unilever: 3%

Moat of Galderma Group AG:

Galderma Group AG has a significant moat in the field of dermatological products, especially due to their strong brand awareness and specialized product lines in skincare and aesthetic medicine. Their research and development in dermatology gives them a technological advantage.

Compared to competitors, Johnson & Johnson has a broader moat due to their diversified product range and global presence. L'Oréal benefits from a strong brand presence and an extensive distribution network.

Galderma's advantage lies in specialization and innovation in the dermatological field, while other companies may benefit from greater product diversification and market presence.

Revenue growth: 10% (2024) Research and development expenditure: 15% of revenue (2024) Market share in dermatology: 20% (2024)

Galderma Group AG recorded a solid revenue growth of 10% in 2024, indicating strong demand for its dermatological products and services. The company continues to invest heavily in research and development, with 15% of revenue allocated to this area. This demonstrates Galderma's commitment to developing innovative solutions and strengthening its market position.

With a market share of 20% in dermatology, Galderma is well positioned to benefit from the increasing demand for skincare products and medical solutions. Continued investment in research and development could lead to new product innovations that further boost growth.

Overall, these factors suggest that Galderma Group AG could be a promising investment, especially for investors interested in long-term growth in the healthcare sector.

Dividend: No current data available (As of 2025)

At the current time, there is no specific information available regarding the dividend policy of Galderma Group AG for the year 2025. Galderma is a company specializing in dermatological products, and it is possible that it reinvests its profits to promote further growth rather than paying out dividends.

Companies in the growth phase often tend not to pay dividends in order to use capital for investments and expansion. It would be advisable to consult the latest financial reports of the company or official announcements to obtain more precise information about the dividend policy.